|
Name
|
Type
|
Target
|
Indications
|
Phase of clinical trials
|
|---|
|
YW327.6S2
|
Monoclonal antibody
|
AXL
|
NSCLC, breast cancer
|
Preclinical
|
|
D9
|
Monoclonal antibody
|
AXL
|
Pancreatic cancer
|
Preclinical
|
|
E8
|
Monoclonal antibody
|
AXL
|
Pancreatic cancer
|
Preclinical
|
|
MAb173
|
Monoclonal antibody
|
AXL
|
Kaposi sarcoma
|
Preclinical
|
|
AXL-107-MMAE
|
Antibody-drug conjugate
|
AXL
|
Melanoma
|
Preclinical
|
|
64Cu-anti-hAXL
|
64Cu-labeled anti-human antibody
|
AXL
|
Breast cancer
|
Preclinical
|
|
Axl specific CAR and SynNotch receptor
|
CAR and synNotch receptors
|
AXL
|
Leukemia
|
Preclinical
|
|
GL21.T
|
RNA nucleotide aptamer
|
AXL
|
NSCLC
|
Preclinical
|
|
GL21.T/miR-34c chimera
|
conjugate of miR-34c and GL21.T
|
AXL
|
NSCLC
|
Preclinical
|
|
DNA AXL-APTAMER
|
DNA nucleotide aptamer
|
AXL
|
Ovarian cancer
|
Preclinical
|
- Abbreviation: NSCLC non-small cell lung cancer
